baito logo
    navigation?.buttons?.createJob?.text
    OSYPKA AG header
    OSYPKA AG logo
    #medizintechnik #herzgesundheit #neurostimulation

    OSYPKA AG

    from Rheinfelden (Baden)

    OSYPKA AG is a leading medical technology company, specializing in innovative devices for invasive cardiology, pediatric cardiac surgery and neurostimulation. The company stands for quality, innovation and social responsibility.

    Visit website

    Company Description: OSYPKA AG

    OSYPKA AG is a leading company in the field of medical technology, specializing in the development and manufacture of innovative medical devices. The company was founded in 1977 by Prof. Dr.-Ing. Peter Osypka in Lörrach, Germany. Today it is based in Rheinfelden and has developed into a significant player in invasive cardiology and pediatric cardiac surgery.

    Key Products and Services

    OSYPKA AG is known for its pioneering work in the development of pacemaker electrodes and radiofrequency ablation for the treatment of cardiac arrhythmias. The company also offers services in the field of neurostimulation, including the development and manufacture of neurostimulators. These products and services are the result of years of research and development carried out by the company.

    Mission and Values

    The mission of OSYPKA AG is to enable every patient to live a long and active life through innovative medical technologies. The company attaches great importance to Excellence, Quality, Integrity, Innovation and Responsibility. These values shape business conduct and help OSYPKA AG to be a respected partner in the medical sector.

    Sustainability and Initiatives

    OSYPKA AG is committed to Safety, Health and Environmental Protection. The company takes care to handle resources carefully and minimize the environmental impact of its business activities. It also promotes the continuous development of its employees and values diversity in the team.

    Current Developments

    Recently, OSYPKA AG has achieved significant milestones, including FDA market approval of an innovative neurostimulator in the USA. In 2022, the company celebrated its 45th anniversary and received the first CE marking according to the new MDR guidelines for Class III products.

    OSYPKA AG is closely associated with the Peter-Osypka-Stiftung, which is committed to social projects and medical-scientific research in the cardiovascular field worldwide. This foundation supports, among other things, pediatric cardiologists and cardiac surgeons in the treatment of children in need.

    Overall, OSYPKA AG is a company that impresses with innovation, quality and social responsibility and is constantly evolving to improve medical care worldwide.

    Sources: